查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1615418

非專利藥注射劑市場：按產品、類型、給藥途徑、容器、應用、分銷管道 - 2025-2030 年全球預測

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Blood Factors, Chemotherapy Agents, Cytokines), Route of Administration, Container, Application, Distribution Channel - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年非專利藥注射劑市值為331.2億美元，預計到2024年將達到365.8億美元，複合年成長率為10.64%，到2030年將達到672.2億美元。

非專利注射劑市場包括與品牌注射劑具有生物等效性但以其通用名稱銷售的藥物。這些產品由於其成本效益、基本藥物的可近性以及對降低醫療保健成本的貢獻，對世界各地的醫院、診所和門診病人設施至關重要。醫療保健系統不斷尋找適應預算緊縮的方法，而非專利注射劑的使用在實現這一目標方面發揮著重要作用。該市場的一個關鍵成長動力是糖尿病和癌症等慢性疾病的日益流行，這些疾病需要頻繁使用注射藥物進行治療。此外，監管環境，特別是專利懸崖形式的支持，為市場擴張提供了有利條件。然而，潛在的挑戰包括嚴格的監管核准流程、定價壓力和製造複雜性，這些可能會阻礙快速進入市場。進一步的限制包括與供應鏈中斷相關的問題以及與製造品質標準相關的高成本。然而，新興市場的需求有機會成長，這些市場的醫療基礎設施正在發展，獲得負擔得起的藥品正成為首要任務。公司可以透過投資本地製造單位和合作夥伴來利用這一趨勢。專注於藥物輸送系統的創新，例如無針注射器和預填充式注射器，可以提高患者的依從性並開拓新的消費群體。生技藥品和生物相似藥也因其以低成本提供複雜治療方法的潛力而成為一個有前途的創新領域。由於市場競爭激烈，且擁有大量大大小小的製藥公司，因此策略重點放在研發以及與醫療保健提供者合作可以推動業務成長。總體而言，推動更永續的醫療保健解決方案強調了推廣非專利注射劑並繼續成為全球健康策略不可或缺的一部分的必要性。

主要市場統計
基準年[2023] 331.2億美元
預計年份 [2024] 365.8億美元
預測年份 [2030] 672.2億美元
複合年成長率（%） 10.64%

市場動態：揭示快速發展的非專利注射劑市場的關鍵市場洞察

供需的動態交互作用正在改變非專利藥注射藥物市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病流行和對具有成本效益的藥物的需求
    • 專利到期增加並強調採用學名藥
    • 政府對學名藥和注射劑的有利核准
  • 市場限制因素
    • 病人和醫生對品牌藥物的偏好
  • 市場機會
    • 正在進行的與非專利注射藥物相關的研究和開發活動
    • 建立非專利注射劑生產的長期策略夥伴關係
  • 市場挑戰
    • 對注射品質和製造差異的擔憂

波特五力：駕馭非專利藥注射藥物市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解非專利藥注射藥物市場的外部影響

外部宏觀環境因素在塑造非專利注射劑市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解非專利注射劑市場的競爭狀況

對非專利藥注射劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 在學名藥市場中的定位非專利供應商績效評估

FPNV定位矩陣是評估非專利注射劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議，規劃非專利注射劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對非專利注射劑市場進行策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和對具有成本效益的藥物的需求
      • 專利到期增加並重視引進學名藥
      • 政府對學名藥和注射劑的有利核准
    • 抑制因素
      • 病人和醫生對品牌藥物的偏好
    • 機會
      • 正在進行的與非專利注射藥物相關的研究和開發活動
      • 生產非專利注射劑的長期策略夥伴關係
    • 任務
      • 對注射品質和製造差異的擔憂
  • 市場區隔分析
    • 產品：由於可用性和熟悉度，各個治療領域小分子注射劑的消費量增加
    • 類型：非專利藥市場探索蓬勃發展的經濟中的動態成長
    • 應用：非專利藥注射劑在心臟病學和腫瘤學領域的顯著優勢需要長期且永續的藥物成本
    • 分銷管道：網路商店因其便利性和有競爭力的價格而越來越受歡迎。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章非專利藥注射劑市場：依產品

  • 聚合物注射
  • 低分子注射液

第7章非專利藥注射劑市場：按類型

  • 血液因素
  • 化療劑
  • 細胞激素
  • 胰島素
  • 單株抗體
  • 胜肽類抗生素
  • 肽激素
  • 疫苗

第8章非專利藥注射劑市場：依給藥途徑分類

  • 肌肉注射 (IM)
  • 靜脈注射 (IV)
  • 皮下注射（SC）

第9章非專利藥市場：依容器分類

  • 安瓿
  • 預填充式注射器
  • 預混合料
  • 管瓶

第10章非專利藥注射劑市場：依應用分類

  • 血液疾病
  • 心臟病學
  • 糖尿病
  • 荷爾蒙失調
  • 免疫學
  • 腫瘤學
  • 疼痛管理

第11章非專利藥注射劑市場：按分銷管道

  • 醫院藥房
  • 網上處方箋商店
  • 零售藥房

第12章美洲非專利藥注射劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區非專利藥注射劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章 歐洲、中東和非洲非專利注射劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Cooper Consumer Health 收購 Viatris 的 OTC 業務
    • Teva 推出 FDA核准的廉價學名藥Victoza，以改善糖尿病治療的可及性
    • Lupin 推出 FDA核准的醋酸加尼瑞克注射液
    • Mayseal Pharmaceuticals 宣布擴大非專利藥注射產品組合
    • 遠藤公司推出諾沙非（Posaconazole）注射液的首個非專利藥
  • 戰略分析和建議

公司名單

  • Amgen Inc.
  • AstraZeneca PLC
  • Aurobindo Pharma Limited
  • Baxter International Inc.
  • Biocon Limited
  • Biological E. Limited
  • Bristol-Myers Squibb Company
  • Cipla Limited
  • Dr. Reddy's Laboratories Ltd.
  • Endo, Inc.
  • Fresenius Kabi AG
  • Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Meitheal Pharmaceuticals, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Samsung Biologics Co., Ltd.
  • Sanofi SA
  • Somerset Pharma, LLC by Mylan
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc. by Cooper Consumer Health
Product Code: MRR-C002B1C997E0

The Generic Injectables Market was valued at USD 33.12 billion in 2023, expected to reach USD 36.58 billion in 2024, and is projected to grow at a CAGR of 10.64%, to USD 67.22 billion by 2030.

The market for generic injectables encompasses pharmaceutical products that are bioequivalent to branded injectables but are sold under their generic names. These products are critical due to their cost-effectiveness, access to essential medications, and contribution to reduced healthcare expenditure, making them essential for hospitals, clinics, and outpatient facilities globally. Health systems relentlessly seek ways to adapt to tightening budgets, and the utilization of generic injectables plays a crucial role in achieving this goal. A significant growth driver in this market is the increasing prevalence of chronic diseases, such as diabetes and cancer, which necessitates frequent use of injectables for treatment. Additionally, regulatory support, particularly in the form of patent cliff opportunities, provides a favorable landscape for market expansion. However, potential challenges include stringent regulatory approval processes, pricing pressures, and manufacturing complexities, which can impede rapid market entry. Furthermore, issues regarding supply chain disruptions and the high costs associated with production quality standards pose limitations. Nonetheless, opportunities arise from the growing demand in emerging markets, where healthcare infrastructure is developing and access to affordable medication is becoming a high priority. Companies can capitalize on this trend by investing in localized manufacturing units and collaborations. Innovations focusing on drug delivery systems-such as needle-free injectables or pre-filled syringes-can enhance patient compliance and open new consumer segments. Biologics and biosimilars are also emerging as promising areas for innovation due to their potential to offer complex therapies at lower costs. As the market is highly competitive, characterized by numerous small and large pharmaceutical companies, maintaining a strategic focus on R&D and forming alliances with healthcare providers can facilitate business growth. Overall, the push for more sustainable healthcare solutions underscores the imperative of advancing generic injectables, ensuring they remain integral in global health strategies.

KEY MARKET STATISTICS
Base Year [2023] USD 33.12 billion
Estimated Year [2024] USD 36.58 billion
Forecast Year [2030] USD 67.22 billion
CAGR (%) 10.64%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generic Injectables Market

The Generic Injectables Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for cost-effective medications
    • Increasing patent expirations and emphasis on adopting generic drugs
    • Favorable government approvals for generic drugs & injectables
  • Market Restraints
    • Preference for branded drugs by patients and physicians
  • Market Opportunities
    • Ongoing R&D activities associated with generic injectable drugs
    • Strategic long-term partnerships to manufacture generic injectables
  • Market Challenges
    • Concerns associated with injectable quality and manufacturing variability

Porter's Five Forces: A Strategic Tool for Navigating the Generic Injectables Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generic Injectables Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generic Injectables Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generic Injectables Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generic Injectables Market

A detailed market share analysis in the Generic Injectables Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generic Injectables Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generic Injectables Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generic Injectables Market

A strategic analysis of the Generic Injectables Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo, Inc., Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC by Mylan, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc. by Cooper Consumer Health.

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Large Molecule Injectables and Small Molecule Injectables.
  • Based on Type, market is studied across Blood Factors, Chemotherapy Agents, Cytokines, Insulin, Monoclonal Antibodies, Peptide Antibiotics, Peptide Hormones, and Vaccines.
  • Based on Route of Administration, market is studied across Intramuscular (IM), Intravenous (IV), and Subcutaneous (SC).
  • Based on Container, market is studied across Ampoules, Prefilled Syringes, Premix, and Vials.
  • Based on Application, market is studied across Blood Disorders, Cardiology, Diabetes, Hormonal Disorders, Immunology, Oncology, and Pain Management.
  • Based on Distribution Channel, market is studied across Hospital Pharmacy, Online Prescription Stores, and Retail Pharmacy.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Exploring the dynamic growth in the booming generic injectables market
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Blood Factors
  • 7.3. Chemotherapy Agents
  • 7.4. Cytokines
  • 7.5. Insulin
  • 7.6. Monoclonal Antibodies
  • 7.7. Peptide Antibiotics
  • 7.8. Peptide Hormones
  • 7.9. Vaccines

8. Generic Injectables Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Intramuscular (IM)
  • 8.3. Intravenous (IV)
  • 8.4. Subcutaneous (SC)

9. Generic Injectables Market, by Container

  • 9.1. Introduction
  • 9.2. Ampoules
  • 9.3. Prefilled Syringes
  • 9.4. Premix
  • 9.5. Vials

10. Generic Injectables Market, by Application

  • 10.1. Introduction
  • 10.2. Blood Disorders
  • 10.3. Cardiology
  • 10.4. Diabetes
  • 10.5. Hormonal Disorders
  • 10.6. Immunology
  • 10.7. Oncology
  • 10.8. Pain Management

11. Generic Injectables Market, by Distribution Channel

  • 11.1. Introduction
  • 11.2. Hospital Pharmacy
  • 11.3. Online Prescription Stores
  • 11.4. Retail Pharmacy

12. Americas Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific Generic Injectables Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa Generic Injectables Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
    • 15.3.1. Cooper Consumer Health's acquisition of Viatris Inc.'s OTC business
    • 15.3.2. Teva launches affordable FDA-approved generic Victoza boosting diabetes care access
    • 15.3.3. Lupin launches FDA-approved Ganirelix Acetate Injection
    • 15.3.4. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
    • 15.3.5. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Amgen Inc.
  • 2. AstraZeneca PLC
  • 3. Aurobindo Pharma Limited
  • 4. Baxter International Inc.
  • 5. Biocon Limited
  • 6. Biological E. Limited
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Limited
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Endo, Inc.
  • 11. Fresenius Kabi AG
  • 12. Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Hikma Pharmaceuticals PLC
  • 15. Johnson & Johnson Services, Inc.
  • 16. Lupin Limited
  • 17. Meitheal Pharmaceuticals, Inc.
  • 18. Merck & Co. Inc.
  • 19. Novartis AG
  • 20. Novo Nordisk A/S
  • 21. Pfizer Inc.
  • 22. Samsung Biologics Co., Ltd.
  • 23. Sanofi S.A.
  • 24. Somerset Pharma, LLC by Mylan
  • 25. Sun Pharmaceutical Industries Ltd.
  • 26. Teva Pharmaceutical Industries Ltd.
  • 27. Viatris Inc. by Cooper Consumer Health

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD FACTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CHEMOTHERAPY AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PEPTIDE HORMONES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAMUSCULAR (IM), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INTRAVENOUS (IV), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SUBCUTANEOUS (SC), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY AMPOULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PREMIX, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY BLOOD DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HORMONAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 47. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 59. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 60. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. CANADA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. CANADA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. MEXICO GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. MEXICO GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 72. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 81. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 88. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 91. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 92. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. CHINA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 94. CHINA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. INDIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 100. INDIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 103. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 104. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 109. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. JAPAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 112. JAPAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 115. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 116. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 121. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 122. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 124. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 127. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 128. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 130. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 133. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 134. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 136. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 139. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 140. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 145. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. THAILAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 148. THAILAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 151. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 152. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 153. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 154. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 158. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 160. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 164. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 165. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. DENMARK GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 167. DENMARK GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 172. EGYPT GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 173. EGYPT GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 176. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 177. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. FINLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 179. FINLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. FRANCE GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 185. FRANCE GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 188. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 189. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. GERMANY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 191. GERMANY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 194. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 195. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 196. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 197. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 200. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 202. ITALY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 203. ITALY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 206. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 208. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 212. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 213. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 218. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 219. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. NORWAY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 221. NORWAY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 224. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 225. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 226. POLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 227. POLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 230. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 232. QATAR GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 233. QATAR GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 236. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 237. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 242. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 243. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 244. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 245. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 254. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 255. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 256. SPAIN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 257. SPAIN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 260. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 261. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 266. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 267. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 268. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 269. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 272. TURKEY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 273. TURKEY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 274. TURKEY GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 275. TURKEY GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY CONTAINER, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 290. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 291. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023